NewcelX Ltd.
About NewcelX Ltd.
NewcelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was established through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., combining advanced stem-cell technologies with neuroscience expertise. It is headquartered in Kloten, Zurich, Switzerland, and operates as a public company listed on NASDAQ under the ticker NCEL. Its main program focuses on cell replacement therapies, including for Type 1 Diabetes and ALS.
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Established via merger of NLS Pharmaceutics and Kadimastem to advance combined cell-therapy and neuroscience platforms.
- Raised $2.875M in private placement alongside $9M in related equity financing and warrant exercises.
- Clinical-stage programs target ALS and Type 1 Diabetes using human pluripotent stem cell technology.
- Headquartered in Kloten, Switzerland with NASDAQ listing under ticker NCEL.
Ask StreetZero about NewcelX Ltd.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account